Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte, Inc. 2022 Q1 - Results - Earnings Call Presentation
04:50am, Thursday, 05'th May 2022 Seeking Alpha
The following slide deck was published by Veracyte, Inc.
Analyst Ratings for Veracyte
07:18pm, Wednesday, 04'th May 2022 Benzinga
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
4
0
1
0
Last 30D
1
Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Veracyte (VCYT) delivered earnings and revenue surprises of 13.04% and 9.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q1 2022 Results - Earning Calls Transcript
08:49pm, Tuesday, 03'rd May 2022
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Giulia
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
08:15am, Tuesday, 19'th Apr 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, M
Is This Under-the-Radar Growth Stock a Buy?
10:50am, Friday, 08'th Apr 2022 The Motley Fool
This genetic diagnostics company could be a good pick for growth investors.
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
09:05pm, Tuesday, 01'st Mar 2022 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
10 Biggest Price Target Changes For Tuesday
11:48am, Tuesday, 01'st Mar 2022 Benzinga
Keybanc cut the price target on Workday, Inc. (NASDAQ: WDAY) from $345 to $312. Workday shares rose 5.7% to $242.00 in pre-market trading.
SVB Leerink lowered Veracyte, Inc. (NASDAQ: VCYT) price t
Veracyte, Inc. 2021 Q4 - Results - Earnings Call Presentation
06:16am, Tuesday, 01'st Mar 2022 Seeking Alpha
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q4 2021 Results - Earnings Call Transcript
04:27am, Tuesday, 01'st Mar 2022 Seeking AlphaVeracyte, Inc. (VCYT) CEO Marc Stapley on Q4 2021 Results - Earnings Call Transcript
11:27pm, Monday, 28'th Feb 2022
Veracyte, Inc. (VCYT) CEO Marc Stapley on Q4 2021 Results - Earnings Call Transcript
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
11:25pm, Monday, 28'th Feb 2022 Zacks Investment Research
Veracyte (VCYT) delivered earnings and revenue surprises of -7.14% and 6.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Veracyte GAAP EPS of -$0.15 beats by $0.04, revenue of $67.3M beats by $4.57M (NASDAQ:VCYT)
09:14pm, Monday, 28'th Feb 2022 Seeking Alpha
Veracyte press release (NASDAQ:VCYT): Q4 GAAP EPS of -$0.15 beats by $0.04.Revenue of $67.3M (+95.1% Y/Y) beats by $4.57M.
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
09:05pm, Monday, 28'th Feb 2022 Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results.
